Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia
Eric I. Zimmerman(Pfizer (United States)), Sharyn D. Baker(The Ohio State University), Clinton F. Stewart(St. Jude Children's Research Hospital), Abhijit Ramachandran(Arog Pharmaceuticals (United States)), Michael S. Roberts(Auburn University), Jassada Buaboonnam, Hiroto Inaba(St. Jude Children's Research Hospital), Shuiying Hu(The Ohio State University), David C. Turner, Laura J. Janke(St. Jude Children's Research Hospital), Shelley Orwick(St. Jude Children's Research Hospital)
Cited by 184
Related Papers
The genomic landscape of hypodiploid acute lymphoblastic leukemia
|Nature Genetics|2013|737
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
|Journal of Clinical Oncology|2010|648
CREBBP mutations in relapsed acute lymphoblastic leukaemia
|Nature|2011|638